<?xml version='1.0' encoding='utf-8'?>
<document id="27682068"><sentence text="A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction."><entity charOffset="35-47" id="DDI-PubMed.27682068.s1.e0" text="Fusidic Acid" /><entity charOffset="49-56" id="DDI-PubMed.27682068.s1.e1" text="CEM-102" /><entity charOffset="83-91" id="DDI-PubMed.27682068.s1.e2" text="Rifampin" /><pair ddi="false" e1="DDI-PubMed.27682068.s1.e0" e2="DDI-PubMed.27682068.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s1.e0" e2="DDI-PubMed.27682068.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27682068.s1.e0" e2="DDI-PubMed.27682068.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s1.e1" e2="DDI-PubMed.27682068.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27682068.s1.e1" e2="DDI-PubMed.27682068.s1.e2" /></sentence><sentence text=" Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in combination with rifampin (RIF)"><entity charOffset="0-13" id="DDI-PubMed.27682068.s2.e0" text=" Fusidic acid" /><entity charOffset="15-17" id="DDI-PubMed.27682068.s2.e1" text="FA" /><entity charOffset="135-143" id="DDI-PubMed.27682068.s2.e2" text="rifampin" /><entity charOffset="145-148" id="DDI-PubMed.27682068.s2.e3" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e0" e2="DDI-PubMed.27682068.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e0" e2="DDI-PubMed.27682068.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e0" e2="DDI-PubMed.27682068.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e0" e2="DDI-PubMed.27682068.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e1" e2="DDI-PubMed.27682068.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e1" e2="DDI-PubMed.27682068.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e1" e2="DDI-PubMed.27682068.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e2" e2="DDI-PubMed.27682068.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s2.e2" e2="DDI-PubMed.27682068.s2.e3" /></sentence><sentence text=" An FA/RIF pharmacokinetic interaction has not previously been described"><entity charOffset="4-6" id="DDI-PubMed.27682068.s3.e0" text="FA" /><entity charOffset="7-8" id="DDI-PubMed.27682068.s3.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s3.e0" e2="DDI-PubMed.27682068.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s3.e0" e2="DDI-PubMed.27682068.s3.e1" /></sentence><sentence text="" /><sentence text=" In a phase 2 open-label randomized study, we evaluated oral FA/RIF vs standard-of-care (SOC) intravenous antibiotics for treatment of hip or knee PJI"><entity charOffset="61-63" id="DDI-PubMed.27682068.s5.e0" text="FA" /><entity charOffset="64-66" id="DDI-PubMed.27682068.s5.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s5.e0" e2="DDI-PubMed.27682068.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s5.e0" e2="DDI-PubMed.27682068.s5.e1" /></sentence><sentence text=" Outcome assessment occurred at reimplantation (week 12) for subjects with 2-stage exchange, and after 3 or 6 months of treatment for subjects with hip or knee debride and retain strategies, respectively" /><sentence text="" /><sentence text=" Fourteen subjects were randomized 1:1 to FA/RIF or SOC"><entity charOffset="42-44" id="DDI-PubMed.27682068.s8.e0" text="FA" /><entity charOffset="45-47" id="DDI-PubMed.27682068.s8.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s8.e0" e2="DDI-PubMed.27682068.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s8.e0" e2="DDI-PubMed.27682068.s8.e1" /></sentence><sentence text=" Pharmacokinetic profiles were obtained for 6 subjects randomized to FA/RIF"><entity charOffset="69-71" id="DDI-PubMed.27682068.s9.e0" text="FA" /><entity charOffset="72-74" id="DDI-PubMed.27682068.s9.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s9.e0" e2="DDI-PubMed.27682068.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s9.e0" e2="DDI-PubMed.27682068.s9.e1" /></sentence><sentence text=" FA concentrations were lower than anticipated in all subjects during the first week of therapy, and at weeks 4 and 6, blood levels continued to decline"><entity charOffset="1-3" id="DDI-PubMed.27682068.s10.e0" text="FA" /></sentence><sentence text=" By week 6, FA exposures were 40%-45% lower than expected"><entity charOffset="12-13" id="DDI-PubMed.27682068.s11.e0" text="FA" /></sentence><sentence text="" /><sentence text=" The sponsor elected to terminate this study due to a clearly illustrated drug-drug interaction between FA and RIF, which lowered FA levels to a degree that could influence subject outcomes"><entity charOffset="130-132" id="DDI-PubMed.27682068.s13.e0" text="FA" /><entity charOffset="104-105" id="DDI-PubMed.27682068.s13.e1" text="FA" /><entity charOffset="111-112" id="DDI-PubMed.27682068.s13.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s13.e1" e2="DDI-PubMed.27682068.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27682068.s13.e1" e2="DDI-PubMed.27682068.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s13.e1" e2="DDI-PubMed.27682068.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s13.e2" e2="DDI-PubMed.27682068.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27682068.s13.e2" e2="DDI-PubMed.27682068.s13.e0" /></sentence><sentence text=" Optimization of FA exposure if used in combination with RIF should be a topic of future research"><entity charOffset="17-19" id="DDI-PubMed.27682068.s14.e0" text="FA" /><entity charOffset="57-58" id="DDI-PubMed.27682068.s14.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.27682068.s14.e0" e2="DDI-PubMed.27682068.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27682068.s14.e0" e2="DDI-PubMed.27682068.s14.e1" /></sentence><sentence text="" /><sentence text=" NCT01756924" /><sentence text="" /></document>